These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

225 related items for PubMed ID: 29439147

  • 21. Weight-loss therapy in type 2 diabetes: effects of phentermine and topiramate extended release.
    Garvey WT, Ryan DH, Bohannon NJ, Kushner RF, Rueger M, Dvorak RV, Troupin B.
    Diabetes Care; 2014 Dec; 37(12):3309-16. PubMed ID: 25249652
    [Abstract] [Full Text] [Related]

  • 22. Liraglutide effects on beta-cell, insulin sensitivity and glucose effectiveness in patients with stable coronary artery disease and newly diagnosed type 2 diabetes.
    Anholm C, Kumarathurai P, Pedersen LR, Nielsen OW, Kristiansen OP, Fenger M, Madsbad S, Sajadieh A, Haugaard SB.
    Diabetes Obes Metab; 2017 Jun; 19(6):850-857. PubMed ID: 28124822
    [Abstract] [Full Text] [Related]

  • 23. Twelve-Week Treatment With Liraglutide as Add-on to Insulin in Normal-Weight Patients With Poorly Controlled Type 1 Diabetes: A Randomized, Placebo-Controlled, Double-Blind Parallel Study.
    Frandsen CS, Dejgaard TF, Holst JJ, Andersen HU, Thorsteinsson B, Madsbad S.
    Diabetes Care; 2015 Dec; 38(12):2250-7. PubMed ID: 26486191
    [Abstract] [Full Text] [Related]

  • 24. Allogeneic Mesenchymal Precursor Cells in Type 2 Diabetes: A Randomized, Placebo-Controlled, Dose-Escalation Safety and Tolerability Pilot Study.
    Skyler JS, Fonseca VA, Segal KR, Rosenstock J, MSB-DM003 Investigators.
    Diabetes Care; 2015 Sep; 38(9):1742-9. PubMed ID: 26153271
    [Abstract] [Full Text] [Related]

  • 25. Efficacy and safety of methionine aminopeptidase 2 inhibition in type 2 diabetes: a randomised, placebo-controlled clinical trial.
    Proietto J, Malloy J, Zhuang D, Arya M, Cohen ND, de Looze FJ, Gilfillan C, Griffin P, Hall S, Nathow T, Oldfield GS, O'Neal DN, Roberts A, Stuckey BGA, Yue D, Taylor K, Kim D.
    Diabetologia; 2018 Sep; 61(9):1918-1922. PubMed ID: 29992370
    [Abstract] [Full Text] [Related]

  • 26. Effects of taspoglutide on glycemic control and body weight in obese patients with type 2 diabetes (T-emerge 7 study).
    Hollander P, Lasko B, Barnett AH, Bengus M, Kanitra L, Pi-Sunyer FX, Balena R.
    Obesity (Silver Spring); 2013 Feb; 21(2):238-47. PubMed ID: 23404788
    [Abstract] [Full Text] [Related]

  • 27. Efficacy and Safety of Once-Weekly Efpeglenatide Monotherapy Versus Placebo in Type 2 Diabetes: The AMPLITUDE-M Randomized Controlled Trial.
    Frias JP, Choi J, Rosenstock J, Popescu L, Niemoeller E, Muehlen-Bartmer I, Baek S.
    Diabetes Care; 2022 Jul 07; 45(7):1592-1600. PubMed ID: 35671039
    [Abstract] [Full Text] [Related]

  • 28. Orlistat 120 mg improves glycaemic control in type 2 diabetic patients with or without concurrent weight loss.
    Jacob S, Rabbia M, Meier MK, Hauptman J.
    Diabetes Obes Metab; 2009 Apr 07; 11(4):361-71. PubMed ID: 19207292
    [Abstract] [Full Text] [Related]

  • 29. Safety, tolerability, pharmacokinetics and pharmacodynamics of AZP-531, a first-in-class analogue of unacylated ghrelin, in healthy and overweight/obese subjects and subjects with type 2 diabetes.
    Allas S, Delale T, Ngo N, Julien M, Sahakian P, Ritter J, Abribat T, van der Lely AJ.
    Diabetes Obes Metab; 2016 Sep 07; 18(9):868-74. PubMed ID: 27063928
    [Abstract] [Full Text] [Related]

  • 30. Beneficial effects of liraglutide on adipocytokines, insulin sensitivity parameters and cardiovascular risk biomarkers in patients with Type 2 diabetes: a prospective study.
    Díaz-Soto G, de Luis DA, Conde-Vicente R, Izaola-Jauregui O, Ramos C, Romero E.
    Diabetes Res Clin Pract; 2014 Apr 07; 104(1):92-6. PubMed ID: 24530118
    [Abstract] [Full Text] [Related]

  • 31. Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study.
    Hermann LS, Scherstén B, Bitzén PO, Kjellström T, Lindgärde F, Melander A.
    Diabetes Care; 1994 Oct 07; 17(10):1100-9. PubMed ID: 7821128
    [Abstract] [Full Text] [Related]

  • 32. Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial.
    Bohula EA, Scirica BM, Inzucchi SE, McGuire DK, Keech AC, Smith SR, Kanevsky E, Murphy SA, Leiter LA, Dwyer JP, Corbalan R, Hamm C, Kaplan L, Nicolau JC, Ophuis TO, Ray KK, Ruda M, Spinar J, Patel T, Miao W, Perdomo C, Francis B, Dhadda S, Bonaca MP, Ruff CT, Sabatine MS, Wiviott SD, CAMELLIA-TIMI 61 Steering Committee Investigators.
    Lancet; 2018 Nov 24; 392(10161):2269-2279. PubMed ID: 30293771
    [Abstract] [Full Text] [Related]

  • 33. Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study.
    Nahra R, Wang T, Gadde KM, Oscarsson J, Stumvoll M, Jermutus L, Hirshberg B, Ambery P.
    Diabetes Care; 2021 Jun 24; 44(6):1433-1442. PubMed ID: 34016612
    [Abstract] [Full Text] [Related]

  • 34. Postpartum treatment with liraglutide in combination with metformin versus metformin monotherapy to improve metabolic status and reduce body weight in overweight/obese women with recent gestational diabetes: A double-blind, randomized, placebo-controlled study.
    Elkind-Hirsch KE, Shaler D, Harris R.
    J Diabetes Complications; 2020 Apr 24; 34(4):107548. PubMed ID: 32046931
    [Abstract] [Full Text] [Related]

  • 35. Vitamin D supplementation improves SIRT1, Irisin, and glucose indices in overweight or obese type 2 diabetic patients: a double-blind randomized placebo-controlled clinical trial.
    Safarpour P, Daneshi-Maskooni M, Vafa M, Nourbakhsh M, Janani L, Maddah M, Amiri FS, Mohammadi F, Sadeghi H.
    BMC Fam Pract; 2020 Feb 07; 21(1):26. PubMed ID: 32033527
    [Abstract] [Full Text] [Related]

  • 36. Inhibition of protein tyrosine phosphatase-1B with antisense oligonucleotides improves insulin sensitivity and increases adiponectin concentrations in monkeys.
    Swarbrick MM, Havel PJ, Levin AA, Bremer AA, Stanhope KL, Butler M, Booten SL, Graham JL, McKay RA, Murray SF, Watts LM, Monia BP, Bhanot S.
    Endocrinology; 2009 Apr 07; 150(4):1670-9. PubMed ID: 19164474
    [Abstract] [Full Text] [Related]

  • 37. Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients.
    Hollander P, Maggs DG, Ruggles JA, Fineman M, Shen L, Kolterman OG, Weyer C.
    Obes Res; 2004 Apr 07; 12(4):661-8. PubMed ID: 15090634
    [Abstract] [Full Text] [Related]

  • 38. Addition of Liraglutide to Insulin in Patients With Type 1 Diabetes: A Randomized Placebo-Controlled Clinical Trial of 12 Weeks.
    Kuhadiya ND, Dhindsa S, Ghanim H, Mehta A, Makdissi A, Batra M, Sandhu S, Hejna J, Green K, Bellini N, Yang M, Chaudhuri A, Dandona P.
    Diabetes Care; 2016 Jun 07; 39(6):1027-35. PubMed ID: 27208343
    [Abstract] [Full Text] [Related]

  • 39. A Randomized, Double-Blind, Placebo-Controlled Trial of Adjunctive Metformin Therapy in Overweight/Obese Youth with Type 1 Diabetes.
    Nwosu BU, Maranda L, Cullen K, Greenman L, Fleshman J, McShea N, Barton BA, Lee MM.
    PLoS One; 2015 Jun 07; 10(9):e0137525. PubMed ID: 26367281
    [Abstract] [Full Text] [Related]

  • 40. Evaluation of weight loss and metabolic changes in diabetic patients treated with liraglutide, effect of RS 6923761 gene variant of glucagon-like peptide 1 receptor.
    de Luis DA, Diaz Soto G, Izaola O, Romero E.
    J Diabetes Complications; 2015 Jun 07; 29(4):595-8. PubMed ID: 25825013
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.